Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

EOLS

Evolus Inc

Apr 16 • 04:00PM ET

12.05

Dollar change +0.16
Percentage change 1.35	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VHT VTWO IWC PTH ITOT VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	21.18%	Shs Outstand	57.82M	Perf Week	-9.33%
Market Cap	741.08M	Forward P/E	74.68	EPS next Y	0.16	Insider Trans	-12.92%	Shs Float	48.47M	Perf Month	-13.31%
Income	-61.69M	PEG	-	EPS next Q	-0.15	Inst Own	75.19%	Short Float	9.59%	Perf Quarter	15.53%
Sales	202.09M	P/S	3.67	EPS this Y	44.61%	Inst Trans	0.64%	Short Ratio	6.94	Perf Half Y	48.03%
Book/sh	-0.36	P/B	-	EPS next Y	146.54%	ROA	-33.62%	Short Interest	4.65M	Perf Year	43.62%
Cash/sh	1.02	P/C	11.79	EPS next 5Y	16.50%	ROE	-1279.29%	52W Range	7.07 - 15.43	Perf YTD	14.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.81%	ROI	-59.04%	52W High	-21.92%	Beta	1.48
Dividend TTM	-	Quick Ratio	2.10	Sales past 5Y	44.65%	Gross Margin	67.00%	52W Low	70.44%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	2.33	EPS Y/Y TTM	18.34%	Oper. Margin	-17.87%	RSI (14)	25.91	Volatility	3.39% 3.20%
Employees	273	Debt/Eq	-	Sales Y/Y TTM	35.98%	Profit Margin	-30.52%	Recom	1.12	Target Price	22.29
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	11.67%	Payout	-	Rel Volume	0.74	Prev Close	11.89
Sales Surprise	1.34%	EPS Surprise	-0.65%	Sales Q/Q	39.76%	Earnings	Mar 07 AMC	Avg Volume	670.08K	Price	12.05
SMA20	-10.40%	SMA50	-12.03%	SMA200	15.90%	Trades		Volume	497,652	Change	1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $16
Jun-23-22	Initiated	Needham	Buy	$18
May-12-22	Upgrade	Barclays	Underweight → Equal Weight	$8 → $10
Jan-20-22	Upgrade	Truist	Hold → Buy	$11
May-06-21	Upgrade	Mizuho	Neutral → Buy	$15
Apr-08-21	Reiterated	H.C. Wainwright	Buy	$20 → $22
Feb-24-21	Downgrade	Truist	Buy → Hold	$12
Jul-07-20	Downgrade	Mizuho	Buy → Neutral	$8 → $3
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform	$25
Sep-05-19	Resumed	Mizuho	Buy	$30
Jun-28-19	Initiated	Wells Fargo	Market Perform	$16
Jun-11-19	Initiated	Barclays	Underweight	$13
Mar-20-19	Initiated	SunTrust	Buy	$30
Feb-14-19	Initiated	H.C. Wainwright	Buy	$37
Jan-29-19	Initiated	Stifel	Buy	$27

Show Previous Ratings

Apr-12-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-24 08:00AM	Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 09:55AM	Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock (Business Wire)
04:05PM	Loading…
Mar-08-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
03:24PM	Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:30PM	Q4 2023 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:34PM	Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 (GuruFocus.com)
09:53PM	EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:30AM	Evolus Announces Results from European Head-to-Head Filler Trial (Business Wire)
Feb-27-24 08:30AM	Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences (Business Wire)
Feb-22-24 04:30PM	Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 (Business Wire)
04:05PM	Loading…
Feb-09-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-02-24 09:10PM	Evolus Inc Director Karah Parschauer Sells 11,931 Shares (GuruFocus.com)
Jan-16-24 05:28PM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance (Business Wire)
Jan-12-24 04:23PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-24 06:21PM	Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High? (Zacks)
Jan-04-24 04:05PM	Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications (Business Wire)
Dec-20-23 08:00AM	Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe (Business Wire)
Dec-08-23 04:30PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-23 09:08AM	Evolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 05:16PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-23 04:16PM	Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau (Business Wire)
Nov-06-23 08:45AM	Extra-Strength 40U Formulation of JeuveauDemonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting (Business Wire)
Nov-01-23 08:45AM	Evolus to Participate in November Investor Conferences (Business Wire)
Oct-25-23 08:45AM	Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting (Business Wire)
08:45AM	Evolus to Report Third Quarter 2023 Results (Business Wire)
06:41PM	Loading…
Oct-08-23 06:41PM	7 Must-Own Small-Cap Stocks That Could Outperform the Market (InvestorPlace)
Sep-29-23 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-23 04:10PM	7 Small-Cap Stocks Analysts Predict Will Double in 2024 (InvestorPlace)
Sep-09-23 01:03PM	Insider Sell: CFO Sandra Beaver Sells 3,178 Shares of Evolus Inc (EOLS) (GuruFocus.com)
Sep-03-23 05:29AM	12 Cheapest and Best Countries for Plastic Surgery (Insider Monkey)
Aug-29-23 08:45AM	Evolus to Participate in September Conferences (Business Wire)
Aug-27-23 07:20PM	Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside Heres Why You Should Pay Attention (TipRanks)
Aug-23-23 06:53PM	Evolus Announces Inducement Grants for New Chief Marketing Officer (Business Wire)
Aug-21-23 08:45AM	Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer (Business Wire)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
08:45AM	Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers (Business Wire)
Aug-02-23 05:45PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Second Quarter 2023 Results and Provides Business Update (Business Wire)
Jul-27-23 11:42AM	Why Shares of Evolus Are Jumping Thursday (Motley Fool) +29.54%
08:45AM	Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue (Business Wire)
Jul-26-23 10:02AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:45AM	Evolus to Participate in Canaccord Genuitys 43rd Annual Growth Conference (Business Wire)
Jul-19-23 08:45AM	Evolus to Report Second Quarter 2023 Results and Provide Business Update (Business Wire)
Jul-15-23 07:30AM	Twitter Faces Threats From AI and Threads (Motley Fool)
Jun-29-23 09:00AM	Evolus Launches Nuceiva® (botulinum toxin type A) in Italy (Business Wire)
Jun-22-23 08:45AM	Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau ® (Business Wire)
Jun-08-23 04:05PM	Evolus Reaches 1 Million Redemptions in its Evolus Rewards Patient Loyalty Program (Business Wire)
Jun-02-23 06:38AM	Positive Signs As Multiple Insiders Buy Evolus Stock \ (Simply Wall St.)
May-16-23 01:44PM	Evolus (NASDAQ:EOLS) rallies 16% this week, taking three-year gains to 161% (Simply Wall St.) -5.91%
May-09-23 05:25PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Evolus Reports First Quarter 2023 Results and Provides Business Update (Business Wire)
04:01PM	Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse, a First-Generation Cold Technology HA by Symatese (Business Wire)
May-05-23 01:37PM	Evolus to Report First Quarter 2023 Results and Provide Business Update (Business Wire)
Apr-17-23 11:05AM	Evolus, Inc.'s (NASDAQ:EOLS) P/S Still Appears To Be Reasonable (Simply Wall St.)
Apr-04-23 10:39AM	Billionaire Israel Englander Goes Big on These 2 Strong Buy Stocks (TipRanks)
Mar-11-23 06:38AM	Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 10:12AM	Q4 2022 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-08-23 05:35PM	Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (Business Wire)
Feb-28-23 08:45AM	Evolus to Participate in the Barclays Global Healthcare Conference (Business Wire)
Feb-27-23 08:45AM	Evolus Initiates Nuceiva® Launch in Germany and Austria (Business Wire)
Feb-22-23 08:45AM	Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update (Business Wire)
Feb-10-23 11:07AM	Evolus Not Affected by Recent Korean Court Ruling (Business Wire)
Jan-31-23 08:45AM	Evolus to Participate in the SVB Securities Global Biopharma Conference (Business Wire) +5.80%
Jan-30-23 12:02PM	Institutional investors own a significant stake of 39% in Evolus, Inc. (NASDAQ:EOLS) (Simply Wall St.)
07:09AM	Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines (Benzinga)
Jan-28-23 08:00AM	"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance (Business Wire)
Jan-23-23 09:00AM	Evolus Receives Regulatory Approval for Nuceiva® in Australia (Business Wire)
08:00AM	Evolus to Present Phase 2 Interim Data from Jeuveau® "Extra-Strength" Dose for Extended Duration Study at 2023 IMCAS World Congress (Business Wire)
Jan-20-23 01:54PM	Why Evolus Shares Jumped This Week (Motley Fool) +5.04%
Jan-19-23 01:15PM	Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook (Benzinga) +5.31%
Jan-18-23 08:45AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration (Business Wire) +18.09%
Jan-03-23 10:03AM	Evolus, Inc.'s (NASDAQ:EOLS) Shift From Loss To Profit (Simply Wall St.)
Dec-08-22 08:45AM	Evolus Extends Term of Credit Facility with Pharmakon Advisors (Business Wire) +7.65%
Dec-07-22 10:00AM	Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc. (PR Newswire)
09:17AM	Shareholders in Evolus (NASDAQ:EOLS) are in the red if they invested three years ago (Simply Wall St.)
Nov-10-22 05:57AM	Evolus Third Quarter 2022 Earnings: Revenues Disappoint (Simply Wall St.) +6.08%
Nov-08-22 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports Third Quarter 2022 Results and Provides Business Update (Business Wire)
Nov-02-22 08:45AM	Evolus to Participate in November Conferences (Business Wire)
Oct-25-22 08:45AM	Evolus to Report Third Quarter 2022 Results and Provide Business Update (Business Wire)
Oct-04-22 08:20AM	Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain (Business Wire)
Sep-21-22 08:45AM	Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022 (Business Wire) -8.71%
Sep-20-22 09:03AM	13 Stocks to Sell Now According to Billionaire Larry Robbins (Insider Monkey)
Sep-18-22 07:30AM	This Options Play Could Turn That Frown Upside Down (TheStreet.com)
Sep-09-22 02:30PM	There's a New Way to Get Rid of Wrinkles (TheStreet.com)
Sep-06-22 04:05PM	Evolus Announces Inducement Grants for New Chief Financial Officer (Business Wire)
Aug-30-22 08:15AM	Evolus Appoints Sandra Beaver as Chief Financial Officer (Business Wire)
Aug-29-22 05:45AM	Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Aug-24-22 08:14AM	Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX® (Business Wire)
Aug-22-22 08:37AM	Owning 42% shares,institutional owners seem interested in Evolus, Inc. (NASDAQ:EOLS), (Simply Wall St.)
Aug-02-22 09:25AM	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -17.62%
08:05AM	Evolus Reports Second Quarter 2022 Results and Provides Business Update (Business Wire)
Jul-19-22 08:45AM	Evolus to Report Second Quarter 2022 Results and Provide Business Update (Business Wire)
08:37AM	Evolus Launches New Campaign Inspiring Consumers to "Switch Your Tox and Love Evolus Forever" (Business Wire)

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOATAZEDI DAVID	See Remarks	Mar 27 '24	Sale	13.86	6,236	86,431	689,614	Mar 29 07:08 PM
MOATAZEDI DAVID	See Remarks	Mar 19 '24	Sale	13.92	96,566	1,344,604	695,850	Mar 21 06:08 PM
Avelar Rui	See Remarks	Mar 19 '24	Sale	13.92	27,603	384,350	372,288	Mar 21 06:09 PM
Beaver Sandra	Chief Financial Officer	Mar 19 '24	Sale	13.92	5,672	78,978	154,201	Mar 21 06:09 PM
MOATAZEDI DAVID	See Remarks	Feb 22 '24	Sale	13.08	7,706	100,804	792,416	Feb 23 08:27 PM
Beaver Sandra	Chief Financial Officer	Feb 22 '24	Sale	13.08	1,821	23,821	159,873	Feb 23 08:27 PM
Avelar Rui	See Remarks	Feb 22 '24	Sale	13.08	1,821	23,821	399,891	Feb 23 08:27 PM
Parschauer Karah Herdman	Director	Jan 30 '24	Sale	13.14	11,931	156,733	31,243	Feb 02 04:57 PM
MOATAZEDI DAVID	See Remarks	Dec 08 '23	Sale	9.73	31,300	304,505	603,944	Dec 08 06:15 PM
MOATAZEDI DAVID	See Remarks	Dec 06 '23	Sale	10.09	51,348	517,891	635,244	Dec 08 06:15 PM
Medytox Inc.	Former 10% Owner	Oct 16 '23	Sale	7.50	1,690,663	12,679,972	3,381,326	Oct 18 04:21 PM
Beaver Sandra	Chief Financial Officer	Sep 06 '23	Sale	9.70	3,178	30,827	113,368	Sep 08 08:54 PM
MOATAZEDI DAVID	See Remarks	Aug 16 '23	Sale	10.27	14,778	151,770	686,592	Aug 16 08:25 PM
Beaver Sandra	Chief Financial Officer	Aug 16 '23	Sale	10.27	2,211	22,707	116,546	Aug 16 08:25 PM
Avelar Rui	See Remarks	Aug 16 '23	Sale	10.27	2,211	22,707	353,386	Aug 16 08:25 PM
Malik Vikram	Director	Aug 15 '23	Buy	7.41	174,967	1,296,505	275,550	Aug 15 04:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EOLS

Evolus Inc

Upgrade your FINVIZ experience